Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Current Assets (2017 - 2025)

Entera Bio has reported Current Assets over the past 9 years, most recently at $15.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 70.51% year-over-year to $15.3 million, compared with a TTM value of $15.3 million through Dec 2025, up 70.51%, and an annual FY2025 reading of $15.3 million, up 70.51% over the prior year.
  • Current Assets came in at $15.3 million for Q4 2025, down from $17.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $28.1 million in Q3 2021 to a low of $7.3 million in Q3 2024.
  • Median Current Assets over the past 5 years was $15.2 million (2022), compared with a mean of $15.8 million.
  • The sharpest move saw Current Assets soared 260.8% in 2021, then tumbled 49.27% in 2022.
  • Over 5 years, Current Assets stood at $25.3 million in 2021, then crashed by 49.27% to $12.8 million in 2022, then dropped by 12.39% to $11.3 million in 2023, then fell by 20.3% to $9.0 million in 2024, then skyrocketed by 70.51% to $15.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Current Assets are $15.3 million (Q4 2025), $17.0 million (Q3 2025), and $19.3 million (Q2 2025).